[The prognostic value of @entity4854 , XXXX and decreased glomerular filtration rate in @entity1187 --pharmacological protection capabilities].

@entity1 @entity1187 @entity32 @entity8 @entity491 @entity26 @entity715 @entity177 @entity413 @entity583 @entity204 @entity4854 @entity65
The evaluation of the risk of complications and @entity204 from cardiovascular causes is conducted in all @entity1 with @entity1187 ( @entity1187 ) using a variety of methods. The assessment of the risk of @entity65 , including also @entity204 , the cause of which are @entity65 , is a very important and essential part of clinical evaluation. Moreover, all @entity1 with @entity1187 are assessed as regards the risk of complications and in-hospital mortality and the short- and long-term @entity1 outcomes. Recently, in the prognostic assessment of @entity1187 @entity1 attention has been paid to @entity4854 , @entity491 , and decreased GFR, which might worsen the prognosis. @entity4854 on admission and especially its occurrence and persistence during hospitalization speak for particularly poor prognosis. Furthermore, the annual and long-term mortality rate is observed to increase with the higher HbA1c level, regardless of the @entity413 concentration on admission to hospital. Increased risk of the occurrence of @entity65 is observed with the intensity of the @entity32 which is reflected, among others, in elevated number of peripheral blood leukocytes. Attention is drawn to the higher rate of complications in @entity1 with @entity491 . The correlation between the increase in leukocyte count and all-cause mortality is statistically significant. A higher risk of non- fatal @entity583 is also observed with the @entity491 . Neutrophils, which are the main pool of white blood cells, and whose activation is observed during PCI, may play a role in these unfavorable phenomena. This activation results in increased production of @entity26 free radicals by these cells, intensification of adhesion and aggregation. A number of studies point to the cardioprotective mechanism of action of statins (anti-inflammatory and anti- @entity715 ) in @entity1 with @entity1187 . The use of leukocyte reduction filters in @entity1 during CABG may be one of the methods limiting the impact of @entity491 on @entity65 in @entity1 with @entity1187 . @entity177 is a strong and independent predictor of mortality in @entity1 with @entity1187 . Contrast-induced @entity8 is a complication following coronarography which is performed in @entity1 with @entity1187 for diagnostic and therapeutic purposes. @entity4854 also has an adverse effect on this complication. The prevention of contrast-induced @entity8 includes the use of statins prior to PCI.
